Brief: Vincerx Pharma Receives Orphan Drug Designation From European Commission For VIP152 For The Treatment Of Diffuse Large B-Cell Lymphoma
07/12/2021 13:15
Dec 7 (Reuters) - Vincerx Pharma Inc VINC.O :
* VINCERX PHARMA RECEIVES ORPHAN DRUG DESIGNATION FROM
EUROPEAN
COMMISSION FOR VIP152 FOR THE TREATMENT OF DIFFUSE LARGE B-CELL
LYMPHOMA
* VINCERX PHARMA INC - CURRENTLY ADVANCING PHASE 1B STUDIES
OF
VIP152 IN MYC-DRIVEN RELAPSED OR REFRACTORY AGGRESSIVE
LYMPHOMAS, ADVANCED SOLID TUMORS
Source text for Eikon: ID:nGNX4chvJT
Further company coverage: VINC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vincerx Pharma
See all newsBrief: Vincerx Pharma Announces Intent To Delist From Nasdaq And Deregister With The SEC
Brief: Vincerx Pharma Announces Termination Of Letter Of Intent And Board Authorization To Pursue Wind-Down Activities
Vincerx Pharma Inc reports results for the quarter ended December 31 - Earnings Summary
Vincerx Pharma Inc expected to post a loss of $3.40 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Aditxt, Natgas companies, DocuSign